Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Share-based Compensation (2017 - 2025)

Dianthus Therapeutics has reported Share-based Compensation over the past 8 years, most recently at $5.8 million for Q3 2025.

  • Quarterly results put Share-based Compensation at $5.8 million for Q3 2025, up 50.89% from a year ago — trailing twelve months through Sep 2025 was $20.7 million (up 113.7% YoY), and the annual figure for FY2024 was $12.9 million, up 344.62%.
  • Share-based Compensation for Q3 2025 was $5.8 million at Dianthus Therapeutics, up from $5.7 million in the prior quarter.
  • Over the last five years, Share-based Compensation for DNTH hit a ceiling of $5.8 million in Q3 2025 and a floor of -$2.7 million in Q3 2022.
  • Median Share-based Compensation over the past 4 years was $1.9 million (2022), compared with a mean of $2.3 million.
  • Biggest five-year swings in Share-based Compensation: crashed 77.45% in 2023 and later skyrocketed 645.43% in 2024.
  • Dianthus Therapeutics' Share-based Compensation stood at $513000.0 in 2022, then skyrocketed by 41.52% to $726000.0 in 2023, then soared by 439.67% to $3.9 million in 2024, then surged by 47.88% to $5.8 million in 2025.
  • The last three reported values for Share-based Compensation were $5.8 million (Q3 2025), $5.7 million (Q2 2025), and $5.3 million (Q1 2025) per Business Quant data.